CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, proudly announced the appointment of Lidia Gardner, PhD, EMBA, as its new Vice President of Clinical and Medical Affairs. Dr. Gardner brings more than 15 years of experience spanning clinical strategy, patient advocacy, evidence generation, medical education, and global scientific leadership in neuromuscular and neuroimmunology diseases.
Dr. Gardner most recently served as Senior Medical Director, Global Medical Affairs – Neurology & Immunology at EMD Serono, a business of Merck KGaA, Darmstadt, Germany. In that role, she led global medical strategy for neuroimmunology programs and collaborated across clinical development, regulatory, real-world evidence, and commercial teams. Prior to joining EMD Serono, she worked in Medical Affairs and clinical development at Novartis, overseeing spinal muscular atrophy and other clinical trials. Earlier in her career, Dr. Gardner served as an Associate Professor of Neurology at the University of Tennessee Health Science Center, where she built and led a translational research program focused on neuroinflammatory and neuromuscular diseases.
As Vice President of Clinical and Medical Affairs, Dr. Gardner will provide strategic medical leadership across CureDuchenne’s research, education, and patient care initiatives. She will work closely alongside CureDuchenne’s Chief Medical Advisor, Brenda Wong, MD, an internationally recognized Duchenne expert, to help advance standards of care, strengthen educational resources, and accelerate therapeutic development for individuals and families affected by Duchenne and Becker muscular dystrophy. Dr. Gardner will also serve as a key spokesperson for CureDuchenne within the medical and scientific communities and help drive strategic partnerships that support the organization’s mission and long-term impact.
“Lidia brings an exceptional combination of scientific expertise and deep commitment to patient-centered care,” said Debra Miller, founder and CEO of CureDuchenne. “Her experience building strong relationships across industry, advocacy, and clinical communities will be instrumental as we continue accelerating research, advancing standards of care, and ensuring families have access to trusted education and support. Lidia understands the urgency facing our community and shares our commitment to driving meaningful progress for everyone affected by Duchenne.”
“I am honored to join CureDuchenne and contribute to an organization that has played such a transformative role in advancing research and care for the Duchenne community,” said Dr. Gardner. “I look forward to partnering with families, clinicians, researchers, and industry leaders to help accelerate therapies, strengthen education and support programs, and continue building momentum toward a future where every individual with Duchenne has access to better care and more treatment options.”
For more similar news, check links below:
ELLKAY Appoints Lucky Singh as Chief Technology Officer
Apothecon Group appoints Shyamakant Giri as the Group CEO
